Table 1 Study patients’ main characteristics
Patient characteristics | n = 337 |
|---|---|
Mean age (mean ± SD) (y) | 73.9 ± 11.8 |
Sex (n, %) | 123 females (36.5%) |
214 males (63.5%) | |
BMI (kg/m2) | 26.4 ± 4.8 |
Risk stratification | |
CHA2DS2-VASc (mean ± SD) | 3.8 ± 1.6 |
Indication for DOAC | |
VTE (n, %) | 96 (28.5) |
AF (n, %) | 241 (71.5) |
Antiplatelet therapy | |
Yes (n, %) | 41 (12.2) |
No (n, %) | 296 (87.8) |
Type of DOAC | |
Rivaroxaban (n, %) | 188 (55.8) |
Apixaban (n, %) | 105 (31.2) |
Edoxaban (n, %) | 31 (9.2) |
Dabigatran (n, %) | 13 (3.9) |
Comorbidities | |
Heart failure (n, %) | 26 (7.7) |
Hypertension (n, %) | 227 (67.4) |
Diabetes (n, %) | 60 (17.8) |
Stroke < 3 months (n, %) | 5 (1.5) |
Stroke > 3 months (n, %) | 40 (11.9) |
VTE < 3 months (n, %) | 12 (3.6) |
VTE > 3 months (n, %) | 84 (24.9) |
Coronary disease (n, %) | 83 (24.6) |
Bioprosthetic valve (n, %) | 7 (2.1) |
Cancer (n, %) | 57 (16.9) |
No comorbidities (n, %) | 28 (8.3) |
Renal function (Cockcroft–Gault) | |
CrCl ≥ 50 ml/min (n, %) | 160 (75.8) |
CrCl = 30–49 ml/min (n, %) | 43 (20.4) |
CrCl < 30 ml/min (n, %) | 8 (3.8) |